Пептидная Регуляция Метаболических Процессов При Гиперхолестеринемических Состояниях Организма

Ляпина, Л. А.; Григорьева, М.Е.; Оберган, Т. Ю.; Шубина, Т. А.; Андреева, Л. А.; Мясоедов, Н. Ф.

doi:10.7868/s0002332915060065

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ещё одним пептидом, содержащим лейцин, был Pro-Gly-Pro-Leu. Этот пептид использовался как профилактическое, так и лечебное антидиабетогенное средство [26][27][28][29]. Показано, что при многократном интраназальном введении Pro-Gly-Pro-Leu не только предупреждал развитие экспериментального аллоксанового диабета, но и оказывал защитное антитромботическое действие, повышая антикоагулянтную и все виды фибринолитической активности.…”

Section: Introductionunclassified

“…Так, в условиях развития инсулинзависимого сахарного диабета данный пептид обладал гипогликемическим действием, то есть проявлял лечебный антидиабетогенный эффект. Поэтому данный пептид может быть отнесен к перспективным антидиабетическим средствам [26]. Кроме того, Pro-Gly-Pro-Leu может быть использован как нейропротектор [27].…”

Section: Introductionunclassified

See 1 more Smart Citation

Stability of prolin-containing peptides in biological media

et al. 2019

View full text Add to dashboard Cite

New data on peptide drugs have been summarized; their high stability is due to both the introduction of Pro-Gly-Pro in various amino acid sequences and the modification of the glyproline fragment itself. Pro-Gly-Pro-Leu, ACTH(6-9)Pro-Gly-Pro, 5-oxo-Pro-Arg-Pro and 5-oxo-Pro-His-Pro-NH2 were used as proline-containing peptides. Tritiated peptides were obtained: Pro-Gly-Pro-Leu with specific radioactivity of 135 Ci/mmol, ACTH(6-9)Pro-Gly-Pro – 26 Ci/mmol, 5-oxo-Pro-Arg-Pro – 60 Ci/mmol and 5-oxo-Pro-His-Pro-NH2 – 75 Ci/mmol. The concentration of Pro-Gly-Pro-Leu, ACTH(6-9)Pro-Gly-Pro, 5-oxo-Pro-Arg-Pro and 5-oxo-Pro-His-Pro-NH2 in the blood was found to be about 200 times more than in the brain for intranasal administration, and in average 600 times more for intravenous administration. The stability of proline-containing peptides in vitro experiments was determined using different commercially available peptidases (leucine aminopeptidases, dipeptidases, carboxypeptidases B and Y), and using nasal mucus, microsomal fraction of the rat brain (IMPC) and rat blood plasma. During peptidase hydrolysis of Pro-Gly-Pro-Leu, the main metabolites were Gly-Pro-Leu, Pro-Gly-Pro, Gly-Pro and Pro-Gly. For ACTH(6-9)Pro-Gly-Pro, the main metabolites were Phe-Arg-Trp-Pro-Gly-Pro and Trp-Pro-Gly-Pro. In peptidase hydrolysis of 5-oxo-Pro-His-Pro-NH2, the major metabolite was 5-oxo-Pro-His-Pro. It was shown that with different methods of peptides administration the composition of the metabolites formed is different. Based on the data obtained, resistance to enzymatic cleavage of peptides and their metabolic pathways were evaluated. Thus, these new data have shown that the above approaches can be used to prolong the action of glyprolines in living objects. In this case, the degradation of proline-containing peptides occurs mainly not due to the action of proteases, but due to other ways of degradation. In general, the data presented in the review indicate the promise of intranasal way of introducing biologically active peptides into the brain of living organisms.

show abstract

Section: Introductionunclassified